These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 3463828)

  • 1. [Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer. CA 125 as a tumor marker. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
    Kaesemann H; Caffier H; Hoffmann FJ; Crombach G; Würz H; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G
    Klin Wochenschr; 1986 Sep; 64(17):781-5. PubMed ID: 3463828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].
    Crombach G; Zippel HH; Würz H
    Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):205-12. PubMed ID: 2408962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
    Sevelda P; Salzer H; Dittrich C; Spona J
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H; Teshima K; Noda K
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
    Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
    Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor markers in gynecologic diseases].
    Geyer H; Kleine W
    Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma.
    Negishi Y; Furukawa T; Oka T; Sakamoto M; Hirata T; Okabe K; Matayoshi K; Akiya K; Soma H
    Gynecol Obstet Invest; 1987; 23(3):200-7. PubMed ID: 3474196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma.
    Zanaboni F; Vergadoro F; Presti M; Gallotti P; Lombardi F; Bolis G
    Gynecol Oncol; 1987 Sep; 28(1):61-7. PubMed ID: 2443433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas.
    Altaras MM; Goldberg GL; Levin W; Bloch B; Darge L; Smith JA
    Gynecol Oncol; 1988 May; 30(1):26-34. PubMed ID: 2452770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
    Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
    Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Ca 125 as tumor marker in ovarian carcinoma.
    Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
    Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination.
    Knauf S; Bast RC
    Int J Biol Markers; 1988; 3(2):75-81. PubMed ID: 3243980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
    Ricolleau G; Chatal JF; Fumoleau P; Kremer M; Douillard JY; Curtet C
    Tumour Biol; 1984; 5(3-4):151-9. PubMed ID: 6594738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
    Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
    Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of pre-operative serum CA 125 in ovarian cancer.
    Cruickshank DJ; Fullerton WT; Klopper A
    Br J Obstet Gynaecol; 1987 Jul; 94(7):692-5. PubMed ID: 2441738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients' sera.
    Dietel M; Arps H; Klapdor R; Müller-Hagen S; Sieck M; Hoffmann L
    J Cancer Res Clin Oncol; 1986; 111(3):257-65. PubMed ID: 3460995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.